药品专利保护强度的选择——以中国和澳大利亚为例(1986-2009)

Optimal Choice of Pharmaceutical Patent Protection Strength——China and Australia(1986-2009)

在医药技术、医药经济和医药产业倍受关注的今天,药品专利保护所具有的激励研发创新、提升科技竞争力、促进信息技术公开的基本功能已经成为医药产业实现跨越式发展的有力保障。根据药品专利保护是立法强度与执法强度两方面综合作用的原则,本文对1986-2009年中国和澳大利亚的药品专利保护强度进行了测算,结果发现:一是两国药品专利保护强度的变化曲线相类似,二是执法强度差异是造成两国药品专利保护强度差距的主要原因。基于此,提出加强药品专利立法保护和优化药品专利执法保护环境的政策建议。

Nowadays medical technology,medicine economy and pharmaceutical industry draw more attention.The fundamental functions of pharmaceutical patent protection,which is to encourage RD,enhance technology competition,and promote the distribution of technological information,have become a strong guarantee for the achievement of leap-forward development of pharmaceutical industry.In accordance with the principle,patent protection is affected by legislation intensity and executive intensity comprehensively;the paper calculated the patent protection strength for pharmaceuticals of China and Australia from 1986 to 2009.The outcome showed that two variation curves are alike,and the main reason for the difference between two countries was the gap of executive intensities.Based on the outcome,policy advice were put forward that to strengthen patent protection for pharmaceuticals and optimize law enforcement environment for pharmaceutical patent.